SCHEMBL18790160

SCHEMBL18790160

Cc1cc(Cl)ccc1C(=O)N1CCCC(C(=O)Nc2cccc(C(C)(C)C)c2)C1c1ccc(CCC(C)(C)O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACKR3 P25106 2/20 0.39
▸ CCR1 P32246 1/20 0.39
▸ P2RX1 P51575 1/20 0.38
▸ GCGR P47871 1/20 0.37
▸ GIPR P48546 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ LMNA P02545 2/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ AVPR2 P30518 3/20 0.35
▸ AVPR1A P37288 2/20 0.35
▸ F2 P00734 2/20 0.35
▸ ABCB11 O95342 1/20 0.35
▸ ADRB2 P07550 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ TBXA2R P21731 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14960520 1.00 ACKR3 (0.39) ACKR3CCR1P2RX1GCGRGIPR
SCHEMBL17805408 1.00 ACKR3 (0.39) ACKR3CCR1P2RX1GCGRGIPR
SCHEMBL14959087 0.95 ACKR3 (0.40) ACKR3CCR1P2RX1GCGRGIPR
SCHEMBL15088254 0.93 EPHX2 (0.39) ACKR3GCGRGIPRRXFP1ALDH1A1
SCHEMBL14960509 0.92 RXFP1 (0.42) ACKR3CCR1GCGRGIPRRXFP1
SCHEMBL18790161 0.92 RXFP1 (0.42) ACKR3CCR1GCGRGIPRRXFP1
SCHEMBL13327392 0.92 RXFP1 (0.42) ACKR3CCR1GCGRGIPRRXFP1
SCHEMBL15088237 0.90 RXFP1 (0.37) ACKR3CCR1GCGRGIPRRXFP1
SCHEMBL24016851 0.88 ACKR3 (0.36) ACKR3CCR1GCGRGIPRRXFP1
SCHEMBL18532713 0.88 ACKR3 (0.36) ACKR3CCR1GCGRGIPRRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4015504-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2022-06-22 — — EP disclosed
EP-3508477-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2021-11-10 — — EP disclosed
EP-3508477-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2019-07-10 — — EP disclosed
EP-3078658-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2019-04-10 — — EP disclosed
US-20170114017-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2017-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114017-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 ACKR3 105/4885CCR1 58/4885P2RX1 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback